Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 13/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 4/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20651466 | 0.85 | NLRP3 (0.48) | NLRP3JAK2 | |
| SCHEMBL22249320 | 0.81 | NLRP3 (0.67) | NLRP3PDPK1APPJAK2 | |
| SCHEMBL22249410 | 0.81 | NLRP3 (0.69) | NLRP3APPJAK2 | |
| SCHEMBL22249432 | 0.81 | NLRP3 (0.72) | NLRP3PDPK1APPJAK2 | |
| SCHEMBL22249451 | 0.81 | NLRP3 (0.72) | NLRP3PDPK1APPJAK2 | |
| SCHEMBL22249449 | 0.80 | NLRP3 (1.00) | NLRP3PDPK1APPJAK2PIK3CA | |
| SCHEMBL22249415 | 0.79 | NLRP3 (0.73) | NLRP3APPJAK2 | |
| SCHEMBL22249489 | 0.79 | NLRP3 (0.67) | NLRP3PDPK1APPJAK2 | |
| SCHEMBL22249414 | 0.79 | NLRP3 (0.67) | NLRP3PDPK1APPJAK2 | |
| SCHEMBL22249447 | 0.79 | NLRP3 (0.67) | NLRP3APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885PDPK1 1333/4885APP 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.